Summary: Twenty-two patients with. Parkinson's disease were treated for the periods, of up to six months with L-dopa. In nine of the male patients metabolic observations were made after oral administration of '4C-L-dopa.
Introduction
L-Dopa (L-3, 4-dihydroxyphenylalanine) has been shown in several studies to be of definite benefit to patients with Parkinson's disease (Cotzias et al., 1968 (Cotzias et al., , 1969 Yahr et al., 1968; Calne et al., .1969 ; Godwin-Austen et al., 1969) . Comparatively little, however, is known of the metabolism of this amino-acid after oral administration of the large doses now regularly used for therapeutic purposes. The present study was undertaken to provide information on the absorption and excretion of '4C-labelled drug in iParkinsonian-patients and to augment the clinical information on the efficacy of the drug by a structured study, objective measurements being used to assess progress. 
Patients

Metabolic Studies
The metabolic studies were conducted on nine of the male patients, divided into three groups. The three subjects in group A received orally 4 mg. of '4C-L-dopa with a specific activity of 26 ,LCi per mg. (Amersham-Searle). Serum and urine total radioactivity were followed for eight'hours and stool for 48 hours. The remaining six patients (group B) were given per os 100 ,uCi of "C-L-dopa (Hoffman-La Roche, Ro. 5-4759) in an identical gelatin capsule. Serum, urine, expired air, and stool were analysed for radioactivity. Blood samples were drawn at one, two, three, four, six, and eight hours, and expired air and urine samples collected at the same times. Urine collections were continued until 12, 24, and 48 hours, and stool collections were made for 48 hours after ingestion of the drug. After three of these six subjects had received L-dopa in therapeutic doses for 100 days (group C), metabolic studies were repeated over an eight-hour period -for blood and urine radioactivity following a further dose of 100 1,Ci of "4C-Ldopa, given together-with a similar dose of the non-radioactive pure L-dopa. Urine.-Urine collections were made in polyethylene bottles containing 10 ml. of 1N HC1. The volume was measured, and 0-2 ml. of the sample was mixed in a scintillation phial with 1 ml. of hydroxide of Hyamine. The sample was then counted in 10 ml. of Bray's (1960) solution.
Expired Air.-Expired air was sampled by obtaining 15-litre volumes of expired air in a meteorological balloon attached to a rubber mouthpiece. Exhaled water vapour was removed in a trap surrounded by dry ice and acetone. The whole of each sample was then bubbled by vacuum extraction through two tubes in series, containing respectively 20 ml. and 10 ml. of hydroxide of Hyamine. Then 1 ml. of each sample was counted for adsorbed '4CO2 in 10 ml. of Bray's solution (Fredrickson and Ono, 1958) .
Stool.-Combined 48-hour stool collections were weighed and homogenized in a Waring Blendor. Two mixed aliquots of each sample were dried to constant weight and flashcombusted with infrared light under oxygen in glass flasks sealed with a rubber septum. After combustion, 3 ml. of hydroxide of Hyamine was injected through the septum, and the 4CO., adsorbed in solution was then counted (Kelly et al., 1961) . serum levels occurred at one hour in group A and at two hours in groups B and C. The larger the dose of L-dopa given, the smaller the peak percentage radioactivity in serum. In groups B and C, with doses in the therapeutic range, patients pretreated with L-dopa for 100 days showed smaller peak serum percentage levels than those not pretreated. Three hours after drug ingestion curves of radioactivity were similar in the three groups.
Mean cumulative excretion of radioactivity in the three groups is shown in Excretion of metabolites in urine occurred at a similar rate in the three groups, except that excretion rate was slightly greater in the pretreated patients. Since the differences are slight and the groups small, it is not possible to conclude that pretreatment with L-dopa enhances excretion of its metabolites.
The clinical evidence for the efficacy of the drug in Parkinson's disease is now established beyond doubt from several studies both of structured non-blinded investigations (Cotzias et al., 1969) and in double-blind controlled studies (Calne et al., 1969; Godwin-Austen et al., 1969) . The observations reported here are further evidence that this drug represents a major advance in the treatment of Parkinson's disease.
Previous reports have suggested that improvement continues beyond three months (Yahr et al., 1968) , and this is confirmed in the present study. 
Introduction
The relationship of the Australia-SH (Au-SH) antigen to the different types of viral hepatitis is still uncertain. The antigen may sometimes be detected in the serum early in the disease, but its frequency in infectious and serum hepatitis appears to vary widely (Table I ). This variation is not likely to be due to difference in laboratory technique as good agreement was obtained when five " anti-Au-SH " sera were compared by the gel-diffusion method (Cossart, Taylor, Vahrman, and Zuckerman, 1969) . It has recently been shown that much lower concentrations of antigen can be detected by the complementfixation test (Shulman and Barker, 1969) . We have therefore used both the gel-diffusion and complement-fixation methods to examine sera from 87 cases of naturally occurring viral hepatitis admitted to the Western Hospital, London, during the past four years and have attempted to correlate the presence of the antigen with the clinical types of the disease.
Patients Studied
Blood and faecal specimens were obtained from 87 patients soon after admission to hospital. None had received blood transfusions and none were associated with a renal dialysis unit or admitted to using narcotic drugs. Patients with clinical or laboratory evidence of infectious mononucleosis or cytomegalovirus infection were excluded from the study. from every patient with hepatitis. There was a period of 11 months after May 1966 during which collection of specimens was suspended.
Two types of viral hepatitis were distinguished: (1) infectious hepatitis (I.H.) with a short incubation period (15 to 40 days) after an injection, contact with another case, or a visit to an endemic area; and (2) serum hepatitis (S.H.) with a long incubation period (60 to 180 days) after an injection or with a history of arthralgia of the small joints.
Patients whose history contained no positive features of either category were placed in the I.H. group. In some patients there were points in favour of both diagnoses, and these have been considered as a third group.
Laboratory Methods
The same antiserum (L.B.) was used for both gel-diffusion and complement-fixation tests. It was obtained from a haemophiliac who had received many transfusions of blood, fresh frozen plasma, and cryoprecipitate. Its specificity has been compared with that of the anti-Au and anti-S.H. reference sera kindly supplied by Dr. B. S. Blumberg and Dr. A. M. Prince respectively. The three sera had almost identical properties in the gel-diffusion test (Cossart et al., 1969) .
The gel-diffusion tests were performed in 1 ', agarose (Prince, 1968) .
The complement-fixation tests were performed by a micromethod with a 4 (x 0-02 ml.) volume technique, overnight fixation at 4°C., and 2' units of complement; 50% endpoints were recorded.
All sera were inactivated at 56°C. for one hour before use and serial twofold dilutions of sera from hepatitis patients were tested against one dilution of indicator serum L.B. which contained 4 units of antibody.
For the indirect test the initial mixtures which contained serial twofold dilutions of the patient's convalescent serum, and 4 units of antigen, were held for three hours at room temperature before serum L.B. and complement were added.
Fixation was then allowed to proceed at 4'C. overnight.
Ten per cent faecal extracts were made in Medium 199 and after centrifugation at 3,000 r.p.m. for 15 minutes the supernatant fluids were tested in the presence of antigen by gel
